TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
WRBY

Warby Parker Inc

Healthcare · Medical Instruments & Supplies

26.30$ +12.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Warby Parker Inc (WRBY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 236 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement WRBY
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
88 88 104 113 139 132 137 133 153 150 149 146 172 166 170 162 200 188 192 191 224 214 222 212 242 236 912
37 37 40 48 55 54 58 57 64 63 64 66 77 75 77 75 90 87 88 88 98 101 102 101 111 99 413
51 51 64 65 84 78 80 76 90 86 84 81 95 91 93 87 110 102 105 103 126 114 120 111 131 136 498
– – 105 12 81 87 172 35 123 118 108 25 107 109 112 33 119 114 111 17 120 114 113 129 129 129 500
56 56 105 70 81 87 172 122 123 118 108 102 107 109 112 109 115 111 111 113 124 118 116 118 129 133 497
-4.6 -4.6 -41 -5.1 3.0 -8.8 -92 -46 -34 -32 -24 -22 -12 -18 -20 -22 -5.1 -9.0 -6.6 -9.4 2.5 -4.5 3.6 -6.9 1.7 3.2 1.6
0.0 0.5 0.1 0.5 0.1 0.4 0.1 0.1 0.1 0.0 0.2 1.4 1.9 – – – – – – – – – – – – – –
-4.9 -4.9 -41 -4.6 3.2 -9.2 -92 -46 -34 -32 -24 -20 -11 -16 -17 -19 -2.6 -6.4 -3.8 -6.8 4.9 -2.5 5.7 -5.1 4.0 5.3 9.9
0.1 0.1 0.2 -0.3 0.1 1.1 -1.1 0.1 0.5 0.0 0.0 -0.1 0.3 0.0 0.3 -0.1 0.1 0.4 0.3 0.1 1.5 -0.8 -0.1 0.9 0.8 0.6 2.2
-5.0 -5.0 -42 -4.3 3.0 -10 -91 -46 -34 -32 -24 -20 -11 -16 -17 -19 -2.7 -6.8 -4.1 -6.9 3.5 -1.8 5.9 -6.0 3.2 4.6 7.7
-0.1 -0.1 -37 0.0 7.7 -3.7 -86 -39 -27 -24 -15 -11 -1.4 -6.7 -7.4 -8.8 8.0 4.7 8.1 5.5 17 9.9 18 8.0 18 35 79

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?